These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21491807)

  • 1. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revocation of General Safety Test Regulations That Are Duplicative of Requirements in Biologics License Applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jul; 80(127):37971-4. PubMed ID: 26155602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Dec; 72(232):68064-70. PubMed ID: 18064770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revision of the requirements for live vaccine processing. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):59000-3. PubMed ID: 17966559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.
    Fed Regist; 1998 Jul; 63(147):40858-71. PubMed ID: 10181717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exceptions or alternatives to labeling requirements for products held by the Strategic National Stockpile. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Feb; 77(24):5696-9. PubMed ID: 22359804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr; 58(61):17093-4. PubMed ID: 10125229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisions to the general safety requirements for biological products--FD. Direct final rule.
    Fed Regist; 1998 Apr; 63(75):19399-403. PubMed ID: 10178869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of primary mode of action of a combination product. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Aug; 70(164):49848-62. PubMed ID: 16121446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop.
    Fed Regist; 1998 Aug; 63(154):42773-4. PubMed ID: 10182565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.